DLGAP2 and type 1 diabetes mellitus: While further work is needed to replicate these findings and elucidate the upstream causes of this POE—due to genomic imprinting or in utero environmental exposures, these results indicate DLGAP2 may be a promising therapeutic epigenetic target for T1D prevention.